Mounjaro manufacturer blasts UK as ‘worst country in Europe’ for drug prices
Weight loss, the pharmaceutical manufacturer Eli Lilly targeted the government, claiming that Britain was probably the worst country in Europe, for the drug pricing.
Dave Ricks, General Manager of the company that makes Mounjaro, Financial times He added less than other nations for the UK’s products and added, orum If this does not change, I don’t think they’ll see many new medicines and I don’t think they’ll see much investment. “
Comments, in the midst of the disappointing announcements of pharmaceutical companies, Merck, the planned $ 1 billion research center and London listed in London Astrazaneca’dan Cambridge’deki 200 million pounds £ £ ranked on a site stopped investing.
Eli Lilly is a US -based company of $ 700 billion (£ 520 billion), which produces products in a large spectrum, including diabetes Mounjaro, with obesity, autoimmune disease and Alzheimer’s.
Some of the dissatisfaction with Mr. Ricks is around the voluntary plan for branded pharmaceutical pricing, access and growth (VPAG), which the pharmaceutical companies have paid back to NHS.
Mr. Ricks said that the plan accused companies for their “their own achievements ve and that they wanted to get rid of the plate plan called VPAG”.
. British Pharmaceutical Industry Association (ABPI) said that negotiations were held in August, but “industry and government could not reach an agreement”.
At the beginning of this month, after Merck’s decision to end England’s expansion plans, a government spokesman said the government had more work to change the landscape in the sciences that it was placed as a key column for industrial growth.
“Britain has become the most attractive place to invest in the world, but we know that there are more work,” he said.
“Thanks to our Life Sciences Sector Plan, we carry out decisive actions to unlock, invest and increase growth.
“We started to unlock billions of private investments by investing £ 600 million in health data research service with WelCome, by committing £ 520 million to the innovative production fund of life sciences.”
The UK’s life science sector is worth 100 billion pounds, which supports more than 300,000 jobs.
